mynth
04/2021MajorityLBO

ICG & Management & Private Investors take majority stake in Domusvi

FRANCE Health Providers / Healthcare Facilities / Nursing Homes EV €1–10bn

Context

DomusVi completed a major capital reorganization, described as a "jumbo-LBO". This transaction allowed founder Yves Journel to increase his ownership from 30% to 49%, while ICG remains a key controlling partner. The group's management team also participated in the round, investing approximately €50 million for a 2% stake. The deal was financed through a robust structure including €1.6 billion in portable senior debt (representing 6.3x EBITDA) and a €400 million PIK (Payment-in-Kind) line provided by ICG. The strategic rationale is to fund a "European conquest" phase, aiming to double the group's revenue to €3.4 billion by 2025. This growth will be driven by massive external acquisitions in Germany, Italy, Belgium, and Portugal, further consolidating DomusVi's position as a dominant European healthcare provider.

Domusvi, which reported an EBITDA margin of [members only] in 2020, is valued in this transaction at an EV/EBITDA multiple of 15x–25x.

-> Deep-dive in Healthcare & Pharma market trends

Target

DomusVi stands as a leading international provider of high-quality elderly care and specialized services. The group operates an extensive cross-border network across Europe and Latin America, encompassing medicalized nursing homes, mental health facilities, and home care agencies. The entity actively executes a targeted buy-and-build strategy aimed at securing and strengthening its premier position within its domestic market. DomusVi’s value proposition is built upon a multi-disciplinary approach to dependency and senior care, seamlessly integrating medicalized residential care, specialized disability centers, and home assistance solutions to deliver a comprehensive support ecosystem for seniors and their families.

Ent. Value

€1–10bn

Equity Value

[members only]

Multiples

EV / Revenue

2x–6x

EV / EBITDA

15x–25x

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2020
€1–10bn
€250–500M
[members only]
2019
€1–10bn
€250–500M
[members only]

Other operations with Domusvi

Other operations with Domusvi
DateAcquirerTargetCountrySector
03/2019DOMUSVIRESIDALYAFRANCENursing Homes
06/2017ICG / MANAGEMENT & PRIVATE INVESTORSDOMUSVIFRANCENursing Homes
10/2016DOMUSVISARQUAVITAESPAINNursing Homes
06/2014PAI PARTNERSDOMUSVIFRANCENursing Homes

Other operations with ICG / Management & Private Investors

Other operations with ICG / Management & Private Investors
DateAcquirerTargetCountrySector
07/2021ICGINFRA GROUPBELGIUMUtilities Networks (Water/Fiber)
05/2021ICGCIRCETFRANCEIT Services
04/2019ICG / MERIEUX EQUITY PARTNERSDOC GENERICIITALYGenerics / Labs
08/2018MANAGEMENT & PRIVATE INVESTORSDESIGUALSPAINFashion & Apparel
07/2018MANAGEMENT & PRIVATE INVESTORSBETJEMAN & BARTONFRANCECoffee & Tea
06/2017ICG / MANAGEMENT & PRIVATE INVESTORSDOMUSVIFRANCENursing Homes
06/2017HG CAPITAL / GIC / MONTAGU PRIVATE EQUITY / ICGVISMA GROUPNORWAYERP, HR & Finance
12/2016ICGPARK HOLIDAYSUNITED KINGDOMHospitality
09/2015ICGCOURTEPAILLEFRANCERestaurants / Chains
06/2015ICGSTELLAFRANCEExternal Joinery

Similar deals in Health Providers

Similar deals in Health Providers
DateAcquirerTargetCountrySector
07/2021OMERSAMEDESGERMANYLabs (Biology)
05/2021INFRATILPACIFIC RADIOLOGY GROUPNEW ZEALANDRadiology
04/2021AMERICAN SECURITIESSIMONMED IMAGINGUNITED STATESRadiology
03/2021EQT PARTNERSCERBA HEALTHCAREFRANCELabs (Biology)
03/2021TRITON PARTNERSBERGMAN CLINICSNETHERLANDSClinics / Hospitals
02/2021SILVER LAKE / NESTLEIVC EVIDENSIAUNITED KINGDOMVet Clinics
12/2020FRESENIUSEUGIN GROUPSPAINOutpatient Care
12/2020ANTIN INFRASTRUCTUREHIPPOCRATES (LAF - LA FARMACIA)ITALYPharmacy
12/2020RADIOLOGY PARTNERSMEDNAX RADIOLOGY SOLUTIONSUNITED STATESRadiology
12/2020MEDIAN KLINIKENPRIORY GROUPUNITED KINGDOMClinics / Hospitals

REFERENCES

Valuation range: EV €1–10bn

Revenue range: €1–10bn

EBITDA range: €250–500M

EV/Revenue range: 2x - 6x

EV/EBITDA range: 15x - 25x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Domusvi by ICG / Management & Private Investors are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

FAQ

What transaction does this page cover?

This page covers the acquisition of a majority stake in Domusvi, a French company specialised in Healthcare Facilities, by ICG and Management & Private Investors in 2021, structured as a leveraged buyout (LBO). This followed an earlier holding cycle initiated in June 2017, when the company was acquired by ICG / Management & Private Investors.

How was the acquisition of Domusvi by ICG valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the €1–10bn band, its EV/EBITDA multiple within the 15x - 25x range, and its EV/revenue multiple within the 2x - 6x range. Exact figures are available to members.

What were Domusvi’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Domusvi generated annual revenue estimated in the €1–10bn range and EBITDA in the €250–500M bracket (FY 2020). Detailed financial figures are available to members.

What sources support the information on this transaction?

Transaction data and operational intelligence were compiled from independent financial press reporting by specialized M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.